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Abstract
Background: Pretargeting-based approaches are being investigated for radioimmunoimaging and therapy applications
to reduce the effective radiation burden to the patient. To date, only a few studies have used short-lived radioisotopes
for pretargeting of antibodies, and such examples with internalizing antibodies are even rarer. Herein, we have
investigated pretargeting methodology using inverse electron-demand Diels-Alder (IEDDA) for tracing two
clinically relevant, internalizing monoclonal antibodies, cetuximab and trastuzumab.
Results: Bioorthogonal reaction between tetrazine and trans-cyclooctene (TCO) was used for tracing cetuximab
and trastuzumab in vivo with a fluorine-18 (t½ = 109.8 min) labelled tracer. TCO-cetuximab or TCO-trastuzumab
was administered 24, 48, or 72 h prior to the injection of tracer to A431 or BT-474 tumour-bearing mice, respectively.
With cetuximab, the highest tumour-to-blood ratios were achieved when the lag time between antibody and tracer
injections was 72 h. With trastuzumab, no difference was observed between different lag times. For both antibodies, the
tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 ± 0.1%ID/g for cetuximab
and 1.5 ± 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution. In vivo IEDDA reaction was observed in the
blood for both antibodies, but with trastuzumab, this was to a much lower degree than with cetuximab.
Conclusions: We could successfully visualize the tumours by using cetuximab and trastuzumab in pretargeted
PET imaging despite the challenging circumstances where the antibody is internalized and there is still some
unbound antibody circulating in the blood flow. This clearly demonstrates the potential of a pretargeted approach for
targeting internalizing antigens and warrants development of pharmacokinetic optimization of the biorthogonal
reactants to this end.
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Background
During recent years, the radiolabelling of clinically rele-
vant monoclonal antibodies (mAbs), like cetuximab and
trastuzumab, has been under intense investigation for
the generation of diagnostic and therapeutic radiophar-
maceuticals that can identify and treat tumours expressing
the target antigen [1]. Traditional radiolabelling methods
of mAbs for PET (positron emission tomography) and
SPECT (single-photon emission computed tomography)
usually involve the use of long-lived radioisotopes, such as
zirconium-89 (t½ = 3.3 days), indium-111 (t½ = 2.8 days),
and iodine-124 (t½ = 4.2 days); the half-lives of which are
matched to the biological half-lives of mAbs. Although the
target-to-background ratios obtained with directly radiola-
belled mAbs are excellent, typically, several hours to days
are required before non-target radioactivity has decreased
to sufficiently low levels necessitating the use of long-lived
isotopes. An additional caveat is the increased radiation
burden to the subject, especially to the bone marrow
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resulting from long circulation time of mAbs. In pretar-
geting, the antibody is radiolabelled in vivo after it has
accumulated to the tumour and most of the unbound
antibody has cleared from the blood flow (Fig. 1), enab-
ling the use of short-lived radioisotopes with dosimetric
benefits [2–4]. Earlier approaches to pretargeting in-
cluded streptavidin-biotin system [5], bispecific antibodies
targeting the antigen with In-DTPA [6] or Y-DOTA [7]
complexes, and antibody-modified oligonucleotide conju-
gates [8]. In the recent years, bioorthogonal chemical reac-
tions have emerged as efficient tools for pretargeted
nuclear imaging of mAbs [2, 4, 9–15]. Bioorthogonal reac-
tions occur under physiological conditions without inter-
fering with or being interfered by any of the native
biochemical processes of the system [16, 17]. The most
studied bioorthogonal reactions for pretargeting are the
strain-promoted alkyne azide cycloaddition (SPAAC) and
the inverse electron-demand Diels-Alder (IEDDA) cyclo-
addition between a tetrazine and a dienophile.
The radioisotopes used in previous in vivo pretargeting
studies have included indium-111 (t½ = 2.8 days) [15,
18], copper-64 (t½ = 12.7 h) [2, 13, 19], technetium-99 m
(t½ = 6.0 h) [12, 20], fluorine-18 (t½ = 109.8 min) [4, 21, 22],
gallium-68 (t½ = 67.6 min) [11], and carbon-11 (t½ =
20.4 min) [23]. The half-life dictates the maximum time
allowed after tracer injection for imaging. With indium-
111, copper-64, and technetium-99 m, the time needed for
the clearance of the tracer from non-target tissues plays a
lesser role because the imaging can be performed several
hours or even days later than the tracer injection. While
the advantage in the use of the latter short-lived radioiso-
topes is that the effective dose to the subject is decreased,
the challenge is to modify the pharmacokinetics of the
tracer to allow for rapid elimination within the imaging
time frame dictated by the shorter half-life. High molar ac-
tivity 18F is nowadays widely available in clinical PET cen-
tres, and the half-life of 109.8 min of 18F allows for
multistep synthesis, the preparation of multiple imaging
doses from one batch of the radiotracer, and transportation
of the tracer to remote sites if needed. Therefore, the choice
of a fluorine-18-labelled tracer balances between the dosi-
metric limitations in the use of the long-lived radiometal-
labelled tracers and the synthetic challenges of short-lived
68Ga- and 11C-labelled ones. In this work, we used a previ-
ously developed 18F-radiolabelled tetrazine tracer, [18F]TAF
[24] (Fig. 1). The radiosynthesis of [18F]TAF is carried out
using [18F]-5-fluoro-5-deoxy-ribose ([18F]FDR) as a pros-
thetic group to radiolabel aminooxy-functionalized tetra-
zine via oxime formation. The fluoroglycosylation with
[18F]FDR is a very attractive choice for radiolabelling tetra-
zines with fluorine-18 since it is a high-yield reaction with
mild reaction conditions compatible with the inherent in-
stability of tetrazines. In addition, by using different linkers
between the tetrazine and the aminooxy group, the struc-
ture of the tetrazine radiotracer can be altered depending
on the application. We have previously used [18F]TAF
successfully for pretargeting of porous silicon (PSi)
nanoparticles after intravenous administration [25].
Although radiotracers labelled with longer-lived radio-
isotopes including 64Cu and 111In have been success-
fully used for pretargeting antibodies previously [9,
15], the time between the injection of the radiotracer
and the start of the imaging acquisition have been ra-
ther long, and this lag time as well as the radiobur-
den to the subject could be decreased further with
radiotracers labelled with shorter-lived isotopes.
Fig. 1 Conceptual representation of a two-step pretargeted method based on IEDDA reaction. The current approach involves the sequential
administration of an antibody, followed by administration of a small molecule radiotracer after 24–72 h. a TCO-modified antibody is administered
first. It circulates for a couple of days and eventually accumulates in the tumour and clears from the blood pool and other non-target tissues.
b After a predetermined lag time, a radiolabelled tetrazine tracer is administered. It reacts selectively with the TCO group attached to the antibody and
the unreacted tracer clears rapidly from the blood. In this work, the used radiotracer was 18F-labelled tetrazine, [18F]TAF. c The antibody can now be
localized via the radiolabel on the tracer. The pretargeting approach with short-lived tracer significantly lowers the radiation burden to the subject
compared to traditional methods where the antibody is directly radiolabelled with a longer-lived radionuclide
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We have previously shown that the higher the molar
activity of the tetrazine radiotracer, the more efficient
the bioorthogonal reaction is in vivo [25], while others
view that diluting the tetrazine radiotracer with addi-
tional non-radiolabelled compound is necessary for
maintaining high reaction rates in vivo [4, 9, 26]. Since
our earlier experiments were done with nanoparticles
that were cleared from the blood rapidly, we selected an
amount of 1:1 ratio of cold TAF tetrazine to the amount
of trans-cyclooctene (TCO) in the antibody because this
has been shown to be successful in the literature specifi-
cally in antibody pretargeting. This approach also pro-
vides both blocking of the excess TCO in the blood as
well as driving of the equilibrium of the bioorthogonal
reaction towards the product.
Herein, we have investigated the efficacy of two-step
pretargeting strategy based on IEDDA reaction for tra-
cing two clinically relevant antibodies, cetuximab and
trastuzumab, with [18F]TAF (Fig. 1) in epidermal growth
factor receptor (EGFR)-positive (A431 epidermoid car-
cinoma) and HER2-positive (BT-474 ductal carcinoma)
xenografts in vivo. Cetuximab binds to the extracellular
domain of the EGFR that is over-expressed and/or acti-
vated in many types of cancer. Trastuzumab is an anti-
HER2 mAb that is used for the treatment of HER2/
neu-positive breast cancers. Both EGFR (ErbB1/HER1)
and HER2/neu (ErbB2) belong to the HER family of
tyrosine kinase receptors. Both cetuximab and trastuzu-
mab exhibit slow pharmacokinetics and are known to
internalize over time [27–31]. In principle, the cell
membrane-bound antibody is the only fraction that is
available for pretargeting with a non-internalizing ra-
diotracer. Notably, the antibodies previously used suc-
cessfully for pretargeted imaging either accumulate to
the tumour at exceptionally high concentrations such
as 5B1 targeting the carbohydrate antigen CA 19.9 in
pancreatic cancer [32, 33] or show high persistence on
the cell surface even when bound to the antigen, like
huA33 targeting a transmembrane glycoprotein in colo-
rectal cancer [9, 34]. In this work, the known internal-
ization of the selected mAbs brings an additional
challenge for the pretargeted system together with the
residual unbound antibody remaining in the blood flow
at the time of tracer injection. Despite these complica-
tions, we could localize the tumour in the PET images,
showing that pretargeted imaging strategies could be ex-
tended to the imaging of a wider selection of antibodies
with careful tailoring of the radiotracer pharmacokinetics.
Methods
Cell lines
Human tumour cell lines A431 (epidermoid carcinoma)
and BT-474 (ductal carcinoma) were obtained from the
American Tissue Culture Collection (ATCC, Manassas,
VA, USA). A431 cells were cultured in DMEM supple-
mented with 10% fetal bovine serum, 4 mM L-glutamine,
4.5 g/l glucose, 1 mM sodium pyruvate, 1.5 g/l sodium
bicarbonate, penicillin, and streptomycin. BT-474 cells
were cultured in DMEM:F-12 (1:1) supplemented with
10% fetal bovine serum, 2 mM L-glutamine, nonessential
amino acids, penicillin, and streptomycin. All media
were purchased from the Media Preparation Facility at
MSKCC (Memorial Sloan Kettering Cancer Center,
New York, NY, USA). Cells were maintained in atmos-
phere containing 5% CO2 at 37 °C. Cells were harvested
and passaged weekly using 0.25% trypsin/0.53 mM
EDTA in HBSS without calcium or magnesium. See
Additional file 1 (section “General Materials and
Methods”) for the information on A549 and SKOV3
cell lines that were used in cell studies.
Antibodies
Multidose formulations of cetuximab were obtained
from ImClone (Erbitux), trastuzumab was obtained from
Genentech (Herceptin), and immunoglobulin G (IgG)
was obtained from Fisher Scientific (Human IgG, Whole
Molecule Control, Invitrogen). Trastuzumab was puri-
fied before use to remove α-α-trehalose dehydrate, L-
histidine, and polysorbate 20 additives. Cetuximab was
also treated analogously before use, although the for-
mulation did not include any possibly interfering ingre-
dients. The purification was done with three altering
steps of size-exclusion chromatography (PD10, GE
Healthcare Life Sciences, Little Chalfont, Buckingham-
shire, UK) and with spin-column centrifugation (Ultra-
cel-50, Amicon, EMD Millipore, Billerica, MA, USA).
DFO-modification of mAbs
Cetuximab was conjugated to desferrioxamine B-p-SCN
(DFO-p-SCN in DMSO, 5 eq) under mildly basic condi-
tions (pH 8.5–8.7). The mixture was incubated for 1 h at
37 °C and shaken at 500 rpm. DFO-cetuximab was puri-
fied with size-exclusion chromatography (PD10) and
with spin-column centrifugation three times (Ultracel-
50, Amicon, 50 kD cutoff ). MALDI mass spectrometry
was used to determine the number of DFO moieties that
had been added to each molecule of cetuximab. DFO-
IgG was prepared in a manner similar to DFO-
cetuximab. Readily conjugated DFO-trastuzumab was a
kind gift from the Radiochemistry & Molecular Imaging
Probes Core Facility at MSKCC.
89Zr-labelling of DFO-mAbs and the isotype IgG control
Zirconium-89 was produced through proton beam bom-
bardment of yttrium foil and isolated in high purity as
89Zr-oxalate at MSKCC according to a previously estab-
lished procedure [35]. [89Zr]Zr-DFO-cetuximab was pre-
pared by the complexation of 89Zr-oxalate with DFO-
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cetuximab. 89Zr-oxalate (114.7 MBq) in 1.0 M oxalic
acid (80 μl) was adjusted to pH 7.1–7.5 with 1.0 M
Na2CO3. After CO2 evolution ceased, DFO-cetuximab
(0.756 mg in 250 μl sterile Chelex-treated PBS) was
added, and the reaction was mixed gently by aspirating
with a pipette. The reaction mixture was incubated at
37 °C for 1 h. [89Zr]Zr-DFO-cetuximab was purified with
size-exclusion chromatography (PD10) and concentrated
with spin-column centrifugation (Ultracel-50, Amicon).
[89Zr]Zr-DFO-trastuzumab and [89Zr]Zr-DFO-IgG were
prepared in a similar manner as [89Zr]Zr-DFO-
cetuximab.
TCO-modification of mAbs and the isotype IgG control
An activated succinimidyl ester of TCO ((E)-cyclooct-4-
en-1-yl (2,5-dioxopyrrolidin-1-yl) carbonate in DMSO,
40 eq) was incubated with mAb for 1 h at RT at pH 8.5–
8.7 and shaken 500 rpm. TCO-mAb was purified with
size-exclusion chromatography (PD10) and with spin-
column centrifugation three times (Ultracel-50). The
resulting modified mAbs were characterized by MALDI
mass spectrometry.
Compound TAF and radiosynthesis of [18F]TAF
No-carrier-added [18F]fluoride was produced in a
18O(p,n)18F nuclear reaction on a GE Healthcare PET
Trace 800 cyclotron using 16.5 MeV protons and
enriched 18O-water. Compound TAF, [18F]TAF (see
Additional file 1: Scheme S1) and its precursors were
synthesized as previously described [24]. Cell uptake
assay was performed to ensure that [18F]TAF has no
cell uptake on its own (see experimental details from
Additional file 1, section 3).
Animal experiments
All animal experiments were carried out in compliance
with protocol approved by the Institutional Animal Care
and Use Committee of Memorial Sloan Kettering Cancer
Center and followed National Institutes of Health guide-
lines for animal welfare. Animals were group housed
with water and food ad libitum. Mice were anaesthetized
with 2% isoflurane/medical air inhalation and 5 × 106
(A431) or 5–10 × 106 (BT-474) cells were inoculated
subcutaneously into the shoulder of 8–10 week-old female
athymic nu/nu nude mice (Charles River, Wilmington,
MA, USA) in a 150 μl suspension of 1:1 fresh media/
Matrigel. For BT-474 tumour-bearing mice 17-β-estradiol
pellets (0.72 mg/60-day release, Innovative Research of
America, Sarasota, FL, USA) were surgically implanted
subcutaneously under isoflurane anaesthesia 6 days before
the cells were inoculated, and the skin was closed with a
single wound clip. The animals received a single injection
of meloxicam (2.0 mg/kg in sterile saline subcutaneously)
for perioperative pain control. After 2 weeks from A431
inoculation and 5 to 7 weeks from BT-474 inoculation,
the appropriate size for experiments (5–10 mm in the
largest diameter) of the tumours was achieved. For all
intravenous injections, conscious mice were gently
warmed with a heat lamp and placed on a restrainer.
The tail was sterilized with alcohol pads, and injection
took place via the lateral tail vein. The animals were
sacrificed with CO2 asphyxiation followed by cervical
dislocation at designated time points after tracer ad-
ministration, and samples of tissues and body fluids
were collected for radioactivity measurements and
weighing. Tissue samples were counted on an auto-
mated gamma counter (Wizard2 3″, PerkinElmer), and
radioactivity decay correction was applied. The ex vivo
biodistribution results were expressed as percentage of
injected radioactivity dose per gram of tissue (%ID/g).
[89Zr]Zr-DFO-mAb and isotype IgG control studies
[89Zr]Zr-DFO-cetuximab (12.1 ± 1.1 MBq, 75 μg, in PBS;
n = 4), [89Zr]Zr-DFO-trastuzumab (7.4 ± 0.1 MBq, 20 μg,
in PBS; n = 3), [89Zr]Zr-DFO-IgG in A431 tumour model
(9.0 ± 0.3 MBq, 75 μg, in PBS; n = 3), and [89Zr]Zr-DFO-
IgG in BT-474 tumour model (4.1 ± 0.2 MBq, 20 μg, in
PBS, n = 3) were administered intravenously. PET im-
aging was performed at 24, 48, 72, 96, and 120 h after
injection of tracer.
Pretargeted experiments
Cetuximab
In the pretargeted cetuximab experiments for group A
(n = 4), TCO-cetuximab (75 μg, 0.5 nmol, 3.1 nmol of
TCO, in PBS) was administered 24, 48, or 72 h prior to
the injection of [18F]TAF (16.3 ± 1.8 MBq, 4.3 ± 0.1 nmol,
in 10% EtOH in PBS) to A431 tumour-bearing mice. In
group B (n = 4), non-radioactive TAF (3.1 nmol, in PBS)
was injected 5 min prior to the injection of [18F]TAF
(17.8 ± 1.7 MBq, 1.2 ± 0.1 nmol, in 10% EtOH in PBS);
otherwise, the experiments were performed as in group
A. Two blocking studies were performed in order to en-
sure the specificity of the binding at the tumour site.
First, TCO-cetuximab (75 μg, 0.5 nmol, 3.1 nmol of
TCO, in PBS) was administered 72 h prior to the in-
jection of [18F]TAF (11.1 ± 1.3 MBq, 2.68 ± 0.05 μmol,
in 10% EtOH in PBS) to A431 tumour-bearing mice
(n = 3). Second, TCO-cetuximab (75 μg, 0.5 nmol,
3.1 nmol of TCO, in PBS) and cetuximab (1875 μg, in
PBS; 25-fold excess to TCO-cetuximab) was adminis-
tered 72 h prior to the injection of [18F]TAF (8.8 ±
1.4 MBq, 4.3 ± 0.1 μmol, in 10% EtOH in PBS) to
A431 tumour-bearing mice (n = 3).
Trastuzumab
With pretargeted trastuzumab in group A (n = 4), TCO-
trastuzumab (20 μg, 0.13 nmol, 0.65 nmol of TCO, in
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PBS) was administered 48 h or 72 h prior to the injec-
tion of [18F]TAF (20.1 ± 1.9 MBq, 1.4 ± 0.1 nmol, in 10%
EtOH in PBS) to BT-474 tumour-bearing mice. In group
B (n = 4), non-radioactive TAF (0.65 nmol, in PBS) was
injected 5 min prior to the injection of [18F]TAF (22.5 ±
2.7 MBq, 0.6 ± 0.1 nmol, in 10% EtOH in PBS); otherwise,
the experiments were performed as in group A. Two
blocking studies were performed in order to ensure the
specificity of the binding at the tumour site. First, TCO-
trastuzumab (20 μg, 0.13 nmol, 0.65 nmol of TCO, in
PBS) was administered 72 h prior to the injection of
[18F]TAF (10.3 ± 0.4 MBq, 0.52 ± 0.01 μmol, in 10% EtOH
in PBS) to BT-474 tumour-bearing mice (n = 3). Second,
TCO-trastuzumab (20 μg, 0.13 nmol, 0.65 nmol of TCO,
in PBS) and trastuzumab (500 μg, in PBS, 25-fold excess
to TCO-trastuzumab) were administered 72 h prior
to the injection of [18F]TAF (8.8 ± 1.4 MBq, 4.3 ±
0.1 μmol, in 10% EtOH in PBS) to BT-474 tumour-
bearing mice (n = 5).
Human IgG isotype control
In the pretargeted IgG experiments, TCO-IgG (75 μg,
0.5 nmol, 1.2 nmol of TCO, in PBS) was administered
72 h prior to the injection of [18F]TAF (12.8 ± 1.2 MBq,
in 10% EtOH in PBS) to A431 tumour-bearing mice
(n = 5), and TCO-IgG (20 μg, 0.13 nmol, 0.32 nmol of
TCO, in PBS) was administered 72 h prior to the in-
jection of [18F]TAF (13.7 ± 0.9 MBq, in 10% EtOH in
PBS) to BT-474 tumour-bearing mice (n = 5).
[18F]TAF alone
Additional control animals received only [18F]TAF (14.2
± 1.8 MBq, 0.7 ± 0.1 nmol, in 10% EtOH in PBS, n =
4).
PET imaging
PET imaging was performed on a microPET Focus
120 dedicated small-animal scanner (Siemens Medical
Solutions, Malvern, PA, USA). Mice were anaesthe-
tized with 2% isoflurane/medical air inhalation ap-
proximately 5 min prior to recording the PET images
and kept under anaesthesia during the PET scan. The
energy and coincidence timing windows were 350–
750 keV and 6 ns, respectively. Data was acquired as
static images with a minimum of 20 million coincident
events. Data were sorted into two-dimensional histo-
grams by Fourier re-binning, and transverse images
were reconstructed by filtered back-projection (FBP)
into a 128 × 128 × 63 (0.72 × 0.72 × 1.3 mm) matrix.
The image data were normalized to correct for non-
uniformity of response of the PET, dead-time count
losses, positron branching ratio, and physical decay to
the time of injection, but no attenuation, scatter, or
partial-volume averaging correction was applied. The
measured reconstructed spatial resolution for the
Focus 120 is approximately 1.6 mm in full width at
half-maximum at the centre of the field of view. The
counting rates in the reconstructed images were con-
verted to percent of injected dose per weight (%ID/g)
by use of a system calibration factor derived from the
imaging of a mouse-sized water-equivalent phantom
containing 18F. Images were analysed by using ASIPro
VM software (Concorde Microsystems).
Statistical analysis
Results of the assays were expressed as mean ± standard
deviation of at least three independent experiments. Two-
tailed paired t test was used to evaluate the statistical sig-
nificance, and the probability of *p < 0.05 and **p < 0.005
were considered statistically significant. The statistical
analysis was carried out using IBM SPSS Statistics 22
(IBM Corporation, Armonk, NY, USA) software.
Results
[89Zr]Zr-DFO-cetuximab, [89Zr]Zr-DFO-trastuzumab and
[89Zr]Zr-DFO-IgG
The immunoreactive fraction of the DFO-cetuximab
was found to be 84.2 ± 1.6% (n = 5) (see Additional file 1,
section 4). On average 1.84 ± 0.17 DFO moieties had
been attached to each molecule of cetuximab. On aver-
age, there were 1.03 DFO moieties per trastuzumab and
the immunoreactivity of DFO-trastuzumab varied be-
tween 86 and 97%. On average, 1.32 ± 0.25 DFO moi-
eties had been attached to each molecule of IgG. Crude
radiolabelling yields and radiochemical purities (ITLC:
50 mM EDTA pH 5) were > 99%. The final radiochemical
purities were > 99% and radiochemical yields were 76.3%,
79.4%, 82.3%, and 45.8% for [89Zr]Zr-DFO-cetuximab,
[89Zr]Zr-DFO-trastuzumab, [89Zr]Zr-DFO-IgG (A431 ex-
periments), and [89Zr]Zr-DFO-IgG (BT-474 experiments),
respectively.
TCO-cetuximab, TCO-trastuzumab and TCO-IgG
An average 6.1 ± 0.1, 4.9 ± 0.1, and 2.43 ± 0.1 TCO moi-
eties had been added to each molecule of cetuximab,
trastuzumab, and IgG, respectively. The immunoreactive
fraction (see Additional file 1, section 4) using in vitro
conjugated [18F]TAF was found to be 93.9 ± 1.0% (n = 5)
and 90.8 ± 1.9% (n = 5) for TCO-cetuximab and TCO-
trastuzumab, respectively. The immunoreactivities of the
TCO-modified mAbs were higher than those of the
DFO-modified mAbs, although there were more TCO
moieties (6.1 and 4.9) than DFO moieties (1.8 and 1.03)
attached per mAb. The higher molecular weight and more
hydrophobic nature of DFO appears to have a slight im-
pact on the number of moieties conjugated, as well as the
immunoreactivity of the mAbs compared to TCO.
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[18F]TAF
The final radiochemical purity was > 99%, the decay-
corrected yield was 62.3 ± 11.3% (n = 5), and the molar
activity varied between 15 and 38 GBq/μmol. The cell up-
take of [18F]TAF was < 1% during the 4 h of observation
in the A549 (EGFR+), BT-474 (HER/neu+), and SKOV3
(HER/neu+) cell lines (see Additional file 1: Figure S1).
Determination of optimal imaging time point for the
pretargeting experiments with 89Zr-labelled antibodies
DFO-cetuximab and DFO-trastuzumab were radiola-
belled with 89Zr to visualize their biodistribution in
A431 and BT-474 xenograft-bearing mice in order to de-
termine the optimal time point (i.e., the highest tumour
accumulation of the mAb) based on maximal tumour-
to-background signal ratio for the pretargeted imaging
experiment. The maximum intensity projections (MIP)
of PET images of [89Zr]Zr-DFO-cetuximab and [89Zr]Zr-
DFO-trastuzumab at different time points after injection
are presented in Fig. 2. Coronal, sagittal, and transverse
planar PET images that intersect the centre of the
tumours and quantified ex vivo biodistribution of
[89Zr]Zr-trastuzumab and [89Zr]Zr-cetuximab are shown
in Additional file 1: Figure S2 and Table S1. Our data
were in good agreement with previously published data
on 89Zr-labelled trastuzumab and cetuximab [36–40].
The antibodies accumulated to the tumour site rapidly,
but clearance from non-target tissues was seen only after
72 h, and the hepatobiliary elimination was more
prominent and persisted longer for cetuximab. However,
due to the known internalization of the used antibodies
that subsequently lowers the surface-residing fraction
available for the IEDDA reaction, time points earlier than
72 h were also investigated in the pretargeting experiment
in order to attain optimal balance between the amount of
surface-bound and freely circulating mAb.
Pretargeting experiments
In vitro pretargeting was performed in order to estimate
the efficiency of pretargeting TCO-cetuximab and TCO-
trastuzumab with [18F]TAF. The binding of [18F]TAF to
TCO-antibody-pretreated cells exceeded the nonspecific
uptake of the 18F-labelelled tetrazine tracer alone over 75-
fold, 20-fold, and 15-fold in BT-474, SKOV3, and A549
cells, respectively (see Additional file 1: Figure S4).
When the [18F]TAF is injected intravenously, it first
encounters the mAb remaining in circulation at that
time point. As a result, our experiments with high molar
activity (15–38 GBq/μmol) [18F]TAF resulted in no ob-
servable tumour uptake (results not shown). Therefore,
in order to prevent all of the injected radiotracer from
reacting with mAb in the blood, some non-radioactive
tracer needs to be added as a carrier. We investigated
the effect of added non-radioactive TAF to the biodistri-
bution of [18F]TAF in two ways (Fig. 3): the same molar
amount of non-radioactive TAF was given to each ani-
mal either by mixing it directly to the [18F]TAF injection
Fig. 2 Maximum intensity projections (MIP) for representative mice
administered with 11.4 MBq of [89Zr]Zr-DFO-cetuximab (a) and 7.3 MBq
of [89Zr]Zr-DFO-trastuzumab (b) at different time points after injection in
A431(a) and BT-474 (b) tumour-bearing mice (n= 3), respectively.
The maximum intensity projections (MIPs) are scaled to the same
percentages (100%) for intensity minimum and maximum to
appropriately compare the images
Fig. 3 Experimental scheme for pretargeted imaging studies. Both
mAb groups (A and B) and the nonspecific IgG control received the
same mass of antibody via lateral tail vein injection. In the mAb
pretargeting experiments, the same total molar amount of non-
radioactive TAF was given to each animal after the designated lag
time of 24, 48, or 72 h either by mixing it directly to the [18F]TAF
injection and reducing its molar activity (group A, n = 4) or by giving
the non-radioactive TAF 5 min prior to administration of [18F]TAF
(group B, n = 4). The lag time of 72 h and the single administration
of the tracer was chosen for the experimental setup for nonspecific
IgG control (n = 5) corresponding to the conditions in which the
mAb pretargeting was the most successful
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(group A) or by giving it intravenously 5 min prior to
[18F]TAF injection (group B).
The in vivo IEDDA reaction was followed with PET
imaging after the injection of [18F]TAF. For both anti-
bodies, the tumour could be visualized from the PET
images and the tumour uptake stayed constant while the
background radioactivity washed out over time. Figure 4
represents PET images at 4 h after the [18F]TAF injec-
tion administered 72 h after the injection of mAb (group
A). There was no observable difference between groups
A and B in PET images (see Additional file 1: Figure S5
for PET images of group B). Results from the ex vivo
biodistribution studies in mice for both pretargeted
cetuximab and pretargeted trastuzumab are presented in
Fig. 5 (see also Additional file 1: Tables S2 and S3). With
cetuximab, the tumour uptake in pretargeted experi-
ments was highest in the 72 h group (3.54 ± 0.45%ID/g
for group A and 3.70 ± 0.13%ID/g for group B). Despite
the addition of the non-radioactive carrier, some in
vivo click reaction was still observed in the blood.
For cetuximab, some background radioactivity was
observed in the liver, lung, kidney, heart, and spleen
probably due to the high blood pool of these non-
target organs and clearance pathways from the liver
and kidney. With cetuximab, a small decrease was ob-
served in the radioactivity levels in the blood in
group B at 72 h (group A, 6.60 ± 0.22%ID/g and
group B, 4.94 ± 1.09%ID/g), which improved the
tumour-to-blood ratio slightly (Table 1). This was not
observed in the other experiments. For trastuzumab,
the radioactivity levels in the blood and at the
tumour site were the same for different lag times and
in groups A and B. Because [18F]TAF eliminates
mostly through renal excretion, the highest radioactiv-
ity levels were observed in the urine. Rather high
radioactivity levels were observed in the intestines
due to the hepatobiliary excretion of [18F]TAF.
Control experiments for nonspecific uptake
89Zr-labelled IgG remained mainly in the blood flow
during the observation time of 5 days (see Additional file 1:
Figures S2 and S3 and Table S1). Due to the enhanced
permeability and retention effect, some nonspecific
tumour uptake of [89Zr]Zr-DFO-IgG was observed in
A431 and BT-474 tumour models (5.64 ± 0.46%ID/g and
5.13 ± 1.22%ID/g, respectively).
Figure 6 represents the radioactivity uptake values in
the tumour for pretargeted cetuximab and trastuzu-
mab with a lag time of 72 h (group A) and control ex-
periments for nonspecific uptake. Blocking studies
with either excess of non-radioactive TAF or excess of
mAb showed statistically significant decrease in the
tumour uptake compared to pretargeted mAb (see
Additional file 1: Table S4 and S5), thus demonstrating
that [18F]TAF binding depends on the interaction of
TCO-mAb with receptors and on the reaction between
[18F]TAF and TCO. Radioactivity accumulated to a sig-
nificantly higher degree in the tumours of mice admin-
istered TCO-mAb compared to those given TCO-IgG.
PET images of the nonspecific uptake controls showed
minimal radioactivity accumulation at the tumour site
(Additional file 1: Figures S6, S7, and S8).
Discussion
For both antibodies, the tumour could be visualized
from the pretargeted PET images, albeit the tumour
Fig. 4 PET images of pretargeted cetuximab in A431 tumour-bearing
mouse in group A (a) and pretargeted trastuzumab in BT-474 tumour-
bearing mouse in group A (b). a 75 μg of TCO-cetuximab (3.1 nmol of
TCO) was administered 72 h prior to the injection of [18F]TAF (4.3
± 0.1 nmol) intravenously (n = 4), and b 20 μg of TCO-trastuzumab
(0.65 nmol of TCO) was administered 72 h prior to the injection of
[18F]TAF (1.4 ± 0.1 nmol) intravenously (n = 4). Coronal (I), sagittal (II),
and transverse (III) planar images intersect the centre of the tumours.
Arrows indicate the locations of the tumour (T), liver (L), and
intestines (In)
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uptake of radioactivity was considerably lower than that
for the 89Zr-labelled mAbs. This is in good agreement
with the cell uptake studies (see Additional file 1: Fig-
ure S1) where we showed that the hydrophilicity of
[18F]TAF prevents cellular internalization of the tracer
alone in EGFR and HER2-positive cell lines, but in vitro
pretargeting with cetuximab and trastuzumab allows
for the internalization of the tracer as a result of the
IEDDA reaction occurring with the mAb on the cell
surface (Additional file 1: Figure S3). The degree of
cell-associated radioactivity, however, is considerably
lower than what is seen either with the DFO-
conjugated 89Zr-labelled mAbs or when [18F]TAF is
allowed to click with the TCO-modified mAb before it
is applied to the cells, as illustrated by the results of the
immunoreactivity assay, corroborating that the internal-
ized fraction of the antibody remains beyond reach for this
tracer.
With cetuximab, the highest tumour-to-blood ratios
were achieved when the lag time between mAb and
tracer injections was 72 h. This is most likely due to the
lower levels of circulating unbound TCO-cetuximab in
the blood flow at the later time point. An additional rea-
son might be the downregulation of the EGF receptor
induced by cetuximab [41], as the internalization rate
slows down at the later time points compared to the
Fig. 5 The ex vivo biodistribution of [18F]TAF and pretargeted cetuximab (a, c) and pretargeted trastuzumab (b, d) in groups A (n = 4) and B
(n = 4). In a and b, the lag time between mAb and [18F]TAF injection is 72 h. All the results presented are at 4 h after [18F]TAF injection. The same
molar amount of non-radioactive TAF was given to each animal either by adding it to the [18F]TAF injection (group A) or by giving it 5 min prior
to [18F]TAF injection (group B). The values represent mean ± standard deviation. %ID/g = percentage injected dose/g. S.I. = small intestine,
L.I. = large intestine. *p < 0.05 and **p < 0.005 (two-tailed paired t test done with IBM SPSS Statistics 22)
Table 1 Tumour-to-tissue ratios for pretargeted cetuximab and trastuzumab at 4 h after the injection of [18F]TAF
Ratio Cetuximab 24 h,
group A
Cetuximab 24 h,
group B
Cetuximab 48 h,
group A
Cetuximab 48 h,
group B
Cetuximab 72 h,
group A
Cetuximab 72 h,
group B
Tumour/blood 0.20 ± 0.03 0.26 ± 0.01 0.24 ± 0.06 0.24 ± 0.01 0.54 ± 0.09 0.77 ± 0.15
Tumour/liver 0.49 ± 0.08 0.76 ± 0.15 0.72 ± 0.25 0.63 ± 0.09 1.31 ± 0.01 1.34 ± 0.20
Tumour/muscle 2.12 ± 0.38 3.41 ± 0.37 2.32 ± 0.58 2.73 ± 1.17 4.54 ± 0.59 5.42 ± 0.86
Trastuzumab 48 h
group A
Trastuzumab 48 h
group B
Trastuzumab 72 h
group A
Trastuzumab 72 h
group B
Tumour/blood 0.57 ± 0.04 0.95 ± 0.22 0.63 ± 0.14 0.73 ± 0.17
Tumour/liver 1.64 ± 0.52 2.50 ± 0.71 1.84 ± 0.38 1.63 ± 0.14
Tumour/muscle 2.18 ± 0.48 4.12 ± 0.51 2.37 ± 0.49 3.17 ± 0.56
The same molar amount of non-radioactive TAF was given to each animal either by adding it to the [18F]TAF injection (group A, n = 4) or by giving it 5 min prior
to [18F]TAF injection (group B, n = 4)
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earlier time points. This might lead to higher fraction of
surface-bound cetuximab accessible for [18F]TAF at the
later time points. With trastuzumab, no difference was
seen between the lag times of 48 h and 72 h. With tras-
tuzumab, the tumour-to-blood ratios have been reported
to improve between 48 and 72 h due to a higher amount
of the mAb at the tumour while the blood levels of un-
bound trastuzumab remain unchanged between these
time points [38, 39]. This explains why we did not ob-
serve any difference in the radioactivity concentration in
the blood between different antibody administration lag
times with pretargeted trastuzumab. Furthermore, al-
though there is more trastuzumab at the tumour at
72 h, the amount of non-internalized trastuzumab avail-
able for the reaction with [18F]TAF might in fact be the
same. Hence, we did not observe increased tumour up-
take at 72 h compared to 48 h.
Houghton et al. and Sharkey et al. have both showed
that it is possible to pretarget an antibody that internalizes
with a tracer that does not internalize [2, 42]. Our work is
in accordance with this finding, but naturally, a more in-
teresting approach would be to use a tracer that would
internalize. In this case, it would be important that the
unreacted radiotracer would not remain inside the cells,
which could be challenging to achieve by tuning the lipo-
philicity of the tracer alone. This might restrict the use of
internalizing radiotracers for pretargeted imaging due to
the high background radioactivity in non-target organs.
Development of a “reverse” approach to Tz/TCO
ligation started with the development of 18F-labelled
TCO by Li et al. [43]. In this reverse approach, the tetra-
zine moiety is attached to the desired platform, e.g., anti-
body or nanoparticle, and the radiolabel is attached to
the TCO counterpart. This approach is very appealing
because the higher hydrophilicity of tetrazine com-
pounds compared to TCO compounds may prevent
hydrophobic burying of the tags to the antibody struc-
ture as reported by Rahim et al. [44] resulting in a higher
effective functional loading on the surface of the plat-
form. The reverse approach has been successfully used
in pretargeted fluorescence live cell imaging, where
tracer pharmacokinetics and metabolism are under-
standably less of a concern than in vivo [45]. However,
utility of 18F-TCO for in vivo pretargeting is very limited
[46]. 18F-TCO enters the brain indicating that this tracer
could also internalize cells, but unfortunately, it was
quickly metabolized in vivo precluding its use for pretar-
geting. A more stable conformationally strained TCO (s-
TCO) has been used in live cell imaging and radiolabel-
ling of biomacromolecules, but not in pretargeted exper-
iments in live animals [47–50]. Darko et al. have
developed even more stable conformationally strained
TCO derivatives (d-TCO) and studied their stability and
reaction kinetics [51]. The in vivo properties of the new
d-TCO are very promising when considering possible in-
ternalizing tracers for pretargeting [22].
A crucial factor for the development of a successful
pretargeted system is the elimination properties of the
radiotracer. Renal clearance should be favoured over the
hepatobiliary excretion in order to avoid unwanted,
long-residing background radioactivity in the gastro-
intestinal tract, as high radioactivity levels in the intestines
hamper the delineation of nearby organs. The pharmaco-
kinetic and elimination profile of a tetrazine can be al-
tered, for example by the addition of a hydrophilic linker
and/or changing the chelator [10]. Comparison of the
structures and biodistribution of the published tetrazines
[2, 4, 9–13, 19, 20, 22] for pretargeted PET imaging shows
that there are multiple factors that contribute to the phar-
macokinetic profile. However, there might be one highly
influencing factor, namely the introduction of positive
charge to a radiopharmaceutical, which can increase the
renal clearance [52, 53]. Despite the non-optimal elimin-
ation kinetics of [18F]TAF, our data shows that it can be
used for the pretargeted PET imaging of antibodies. Given
that this approach for pretargeting cetuximab and trastu-
zumab is intended for the imaging of tumours outside the
abdominal area, the hepatobiliary excretion would not
interfere with the image analysis as much as it would in
orthotopic colorectal tumour models. The three hydroxyl
groups in the [18F]TAF precursor, [18F]-5-fluoro-5-deoxy-
ribose ([18F]FDR), lower the lipophilicity of the radiola-
belled oxime product, which is desired for fast urinary
elimination. However, [18F]TAF has some uptake in the
Fig. 6 Tumour uptake values for pretargeted cetuximab and
trastuzumab (group A) and nonspecific uptake controls. Nonspecific
uptake controls include pretargeted TCO-cetuximab with excess of
non-radioactive TAF (blue), pretargeted TCO-cetuximab with excess of
mAb (green), and TCO modified immunoglobulin G pretargeted with
[18F]TAF (red). The results presented are at 4 h after [18F]TAF injection.
The antibody was given 72 h prior to the injection of [18F]TAF. The
values represent mean ± standard deviation. %ID/g = percentage
injected dose/g. *p < 0.05 and **p < 0.005 (two-tailed paired t test done
with IBM SPSS Statistics 22)
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gastrointestinal tract and further optimization of the
pharmacokinetics of [18F]TAF is needed to improve the
present system. The structure of [18F]TAF, however, can
be modified by attaching almost any linker between the
tetrazine and the aminooxy groups. The radiolabelling
could still be done by using [18F]FDR as a prosthetic
group, making the oxime radiolabelling approach very ap-
pealing to be used with tetrazines due to the mild reaction
conditions of the glycosylation. The oxime formation with
[18F]FDR is a high-yield reaction that can be performed in
room temperature in 10 min. The optimization of the
structure of [18F]TAF towards renal clearance, however,
fell beyond the scope of this work.
Recently Knight et al. presented a new pretargeted ap-
proach called HaloTag enzyme for the pretargeting of
two targets: internalizing HER2 and non-internalizing
TAG-72 [18]. Although the HaloTag enzyme could be
used for pretargeting TAG-72 in vivo and was capable of
detecting HER2 expression in vitro, it lacked the sensitiv-
ity for in vivo pretargeting of trastuzumab. The tumour
uptake in the pretargeted trastuzumab experiments did
not reach values significantly higher than that in pretar-
geted IgG. In our experiments, while the tetrazine tracer
accumulated to the tumour in higher degree in the pretar-
geted trastuzumab experiments than in the pretargeted
IgG experiments, the radioactivity accumulation in the
tumour was not nearly as high as with directly radiola-
belled [89Zr]Zr-DFO-trastuzumab. Both pretargeting ap-
proaches clearly faced the same challenge of an
internalizing target antigen rapidly localizing in the cellu-
lar compartment beyond the reach of the radiotracer,
prompting the future development of internalizing
bioorthogonal reagents for the pretargeted imaging of
trastuzumab.
Evans et al. have pretargeted cetuximab with a 68Ga
tracer with 23-h lag time [11]. They observed high back-
ground levels in non-target organs. In our study, we ob-
served some unbound antibody circulating even after a
lag time of 72 h between the antibody and radiotracer
injections. A lucrative strategy for the optimization of
pretargeted systems involving long-circulating antibodies
might be the use of antibody-clearing agents [54, 55].
With these agents, it might be possible to reduce the
amount of circulating TCO-antibody in the blood and
improve tumour delineation. This could be beneficial in
two ways: (i) to improve the in vivo IEDDA reaction
yield at the tumour site and (ii) to reduce the lag time
between the antibody and tracer injection so that more
antibody is still on the surface of the tumour cells and
available for reacting with the non-internalizing tracer.
However, the synthetic development of efficient TCO-
scavenging clearing agents is still in its infancy limiting
wider adaptation of the technique to pretargeted PET
studies at present.
Conclusions
We have pretargeted two clinically relevant monoclonal
antibodies by using 18F-tracer under challenging condi-
tions, wherein the mAb is internalized and unbound
mAb remains in circulation, and demonstrated that a
specific, bioorthogonal IEDDA reaction takes place at
the tumour despite these challenges. This demonstrates
the potential of the pretargeted approach for targeting of
rapidly internalizing antigens expanding the scope of
bioorthogonal chemistry for the development of molecu-
lar imaging tools for a wider variety of antibodies and
intracellular targets. In our case, some further opti-
mization of the pharmacokinetics of the tracer is still
needed for reduction of the background radioactivity in
the excretory organs. Besides the pharmacokinetic
optimization of the tetrazine tracer structure, the use of
an antibody clearing agent could be beneficial in the
models used in order to reduce the observed high radio-
activity levels in the blood remaining even after 72 h of
antibody administration. It might also make it possible
to shorten the time between the antibody and tracer in-
jections, when a higher concentration of the TCO-
modified antibody still resides in the cell surface avail-
able for the in vivo IEDDA reaction.
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